Meeting
2022 ASCO Annual Meeting
Outcomes of combined ipilimumab/nivolumab in metastatic uveal melanoma: A prevalence meta-analysis.
Authors
Ceren Durer
SUNY Upstate Medical University, Syracuse, NY
Ceren Durer , Seren Durer , Gilles Jad Hoilat , Ahmed Abu-Zaid , Mohammed M. Milhem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9534)
DOI
10.1200/JCO.2022.40.16_suppl.9534
Abstract #
9534
Poster Bd #
127
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
First Author: Scott N. Gettinger
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Randomized phase 2 study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in pretreated patients with metastatic biliary tract cancer.
First Author: Alice Markussen
Poster
2022 ASCO Annual Meeting
Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.
First Author: Thaïs M.L. Tong
Poster
2019 ASCO Annual Meeting
Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
First Author: Meredith Pelster